Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Panel Supports Subcutaneous Rituximab for Blood Cancers

March 29th 2017

The FDA's Oncologic Drugs Advisory Committee unanimously (11-0) recommended approval of subcutaneous rituximab for the treatment of patients with certain blood cancers.

FDA Warning Links Breast Implants to ALCL

March 29th 2017

Breast implants may increase an individual’s risk of developing anaplastic large cell lymphoma, a recent FDA advisory warned.

MCL Landscape Shifting With Combo Regimens on Horizon

March 27th 2017

Andre Goy, MD, highlights what researchers can expect next in the field of mantle cell lymphoma, given recent pivotal data from clinical trials.

Pembrolizumab Recommended for EU Approval in Hodgkin Lymphoma

March 25th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.

Dr. Garfall on Impact of CAR T-Cell Therapy in Hematologic Malignancies

March 22nd 2017

Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Expert Discusses Success of Blinatumomab in ALL

March 21st 2017

Hagop Kantarjian, MD, discusses the success of blinatumomab and next steps with the anti-CD19 agent.

Expert Discusses Promise of Quizartinib in AML

March 15th 2017

Mark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.

Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma

March 15th 2017

David J. Straus, MD, internist and hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) as a treatment for patients with Hodgkin lymphoma.

FDA Approves Pembrolizumab for Hodgkin Lymphoma

March 15th 2017

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with classical Hodgkin lymphoma (cHL) who are refractory or have relapsed after 3 or more lines of therapy.

FDA Places Partial Clinical Hold on Selinexor Trials

March 14th 2017

The FDA has placed a partial clinical hold on trials of selinexor (KPT-330), which is being explored in several tumor types.

Imatinib Continues to Impress in Long-Term CML Analysis

March 10th 2017

Imatinib continued to show dramatic overall survival benefits after nearly 11 years of follow-up despite crossover for patients with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase.

Lonial Discusses Dramatic Progress in Multiple Myeloma

March 8th 2017

Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.

Pan-Kinase Inhibition Key to Midostaurin Benefit in AML

March 7th 2017

FLT3 targeted agents are emerging in the treatment of acute myeloid leukemia, and which specific agent will be most effective is highly dependent on whether a patient has been previously treated.

FDA Lifts Clinical Hold on Vadastuximab Talirine Trials in AML

March 6th 2017

The FDA has lifted its clinical hold on several phase I trials of the antibody-drug conjugate vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia.

Expert Discusses JCAR017 CAR T-Cell Therapy in Non-Hodgkin Lymphoma

March 6th 2017

Leo I. Gordon MD, discusses results from the TRANSCEND trial and the next steps with chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma.

Juno Accelerates Development of JCAR017, Halts JCAR015

March 2nd 2017

Juno therapeutics has shifted its focus toward the development of JCAR017 for relapsed/refractory diffuse large B-cell lymphoma after a series of toxicity-related setbacks culminated in the need to halt the development of JCAR015.

NEJM Data Highlight Blinatumomab OS Benefit in Acute Lymphoblastic Leukemia

March 2nd 2017

Treatment with blinatumomab (Blincyto) led to a median overall survival of 7.7 months versus 4 months with standard chemotherapy in patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to results from the phase III TOWER study published in The New England Journal of Medicine.

Ibrutinib Benefit in Waldenstrom Macroglobulinemia Sustained With Latest Data

March 2nd 2017

Single-agent ibrutinib induced a response rate of 90% at a median follow-up of 18.1 months in rituximab-refractory patients with Waldenstrom macroglobulinemia, according to results from an open-label substudy of the ongoing phase III iNNOVATE trial published in The Lancet Oncology.

FDA Grants Priority Review to Enasidenib for IDH2-Mutant AML

March 1st 2017

The FDA has granted a priority review to a new drug application for enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia.

Pivotal Year Looms for CAR T-Cell Therapies

March 1st 2017

Chimeric antigen receptor T-cell therapies have already produced clinical trial results that, even by the lofty standards set by emerging immunotherapies, have been stunning.